The Readout Loud

Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum

Apr 28, 2022
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 2min
2
Novartis Recruits Sandford Bernstein Analyst Ronnie Gow
02:11 • 2min
3
Where Are Cod Ovaxines for Kids Under Five?
04:09 • 4min
4
Biotec Stocks
07:44 • 2min
5
Biotex Oks
09:50 • 2min
6
Carta's Engineered and K Cell Therapies Induce Complete Remissions
11:26 • 2min
7
The Role of N K Cells in Cancer Treatments
13:33 • 2min
8
Is Encasas a Good Source of Iminetherapy?
15:15 • 2min
9
Is Umbilical Cort Blood a Source of Induced Potent Stem Cells?
17:27 • 3min
10
The Safety Switch in the Event of Toxicity
20:25 • 3min
11
The Persistence of Enca Cels Responses
23:00 • 6min